Bath psoralen plus ultraviolet-A photochemotherapy for chronic graft-versus-host disease: a retrospective cohort study.
Journal
International journal of dermatology
ISSN: 1365-4632
Titre abrégé: Int J Dermatol
Pays: England
ID NLM: 0243704
Informations de publication
Date de publication:
Oct 2023
Oct 2023
Historique:
revised:
20
05
2023
received:
28
12
2022
accepted:
01
08
2023
medline:
20
9
2023
pubmed:
12
8
2023
entrez:
12
8
2023
Statut:
ppublish
Résumé
Chronic graft-versus-host disease is a severe complication of allogeneic stem cell and bone marrow transplantation. First-line immunosuppressive agents, such as steroids, are used to prevent this disease; however, they have multiple side effects. Therefore, bath psoralen plus ultraviolet-A (PUVA) is an alternative second-line treatment. This study aimed to evaluate the clinical efficacy of bath PUVA for managing chronic graft-versus-host disease. This retrospective, case-control study included 14 patients with extensive cutaneous chronic graft-versus-host disease, resistant to systemic corticosteroid, treated with bath PUVA. Major and partial responses were defined as clinical improvements of >70% and 50-70%, respectively. We analyzed the graft-versus-host disease clinical presentation and timing after allogeneic stem cell and bone marrow transplantation, bath PUVA doses, background diseases, additional treatments, and adverse effects. We observed eight major (three lichenoid and five sclerodermatoid) and six partial (three lichenoid and three sclerodermatoid) responses after a mean of 28 treatment sessions. After 6 to 25 months, four of the eight patients with sclerodermatoid lesions and all those with lichenoid lesions experienced relapse but responded to additional treatment cycles. Bath PUVA is well-tolerated and effective for extensive cutaneous chronic graft-versus-host disease. It allows rapid tapering of adjuvant immunosuppressants; however, most patients require prolonged maintenance phototherapy.
Sections du résumé
BACKGROUND
BACKGROUND
Chronic graft-versus-host disease is a severe complication of allogeneic stem cell and bone marrow transplantation. First-line immunosuppressive agents, such as steroids, are used to prevent this disease; however, they have multiple side effects. Therefore, bath psoralen plus ultraviolet-A (PUVA) is an alternative second-line treatment. This study aimed to evaluate the clinical efficacy of bath PUVA for managing chronic graft-versus-host disease.
METHODS
METHODS
This retrospective, case-control study included 14 patients with extensive cutaneous chronic graft-versus-host disease, resistant to systemic corticosteroid, treated with bath PUVA. Major and partial responses were defined as clinical improvements of >70% and 50-70%, respectively. We analyzed the graft-versus-host disease clinical presentation and timing after allogeneic stem cell and bone marrow transplantation, bath PUVA doses, background diseases, additional treatments, and adverse effects.
RESULTS
RESULTS
We observed eight major (three lichenoid and five sclerodermatoid) and six partial (three lichenoid and three sclerodermatoid) responses after a mean of 28 treatment sessions. After 6 to 25 months, four of the eight patients with sclerodermatoid lesions and all those with lichenoid lesions experienced relapse but responded to additional treatment cycles.
CONCLUSIONS
CONCLUSIONS
Bath PUVA is well-tolerated and effective for extensive cutaneous chronic graft-versus-host disease. It allows rapid tapering of adjuvant immunosuppressants; however, most patients require prolonged maintenance phototherapy.
Substances chimiques
Ficusin
KTZ7ZCN2EX
Immunosuppressive Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1261-1265Informations de copyright
© 2023 the International Society of Dermatology.
Références
Ratanatharathorn V, Ayash L, Lazarus HM, Fu J, Uberti JP. Chronic graft-versus-host disease: clinical manifestation and therapy. Bone Marrow Transplant. 2001;28:121-129.
Ferrara JL, Deeg HJ. Graft-versus-host disease. N Engl J Med. 1991;324:667-674.
Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant. 2005;11:945-956.
Bassim CW, Fassil H, Mays JW, Edwards D, Baird K, Steinberg SM, et al. Oral disease profiles in chronic graft versus host disease. J Dent Res. 2015;94:547-554.
Munir SZ, Aylward J. A review of ocular graft-versus-host disease. Optom Vis Sci. 2017;94:545-555.
McDonald GB, Sullivan KM, Schuffler MD, Shulman HM, Thomas ED. Esophageal abnormalities in chronic graft-versus-host disease in humans. Gastroenterology. 1981;80:914-921.
Soubani AO, Uberti JP. Bronchiolitis obliterans following haematopoietic stem cell transplantation. Eur Respir J. 2007;29:1007-1019.
Aractingi S, Chosidow O. Cutaneous graft-versus-host disease. Arch Dermatol. 1998;134:602-612.
Janin-Mercier A, Devergie A, Van Cauwenberge D, Saurat JK, Bourges M, Lapiere CM, et al. Immunohistologic and ultrastructural study of the sclerotic skin in chronic graft-versus-host disease in man. Am J Pathol. 1984;115:296-306.
Cutler C, Miklos D, Kim HT, Treister N, Woo SB, Bienfang D, et al. Rituximab for steroid-refractory chronic graft-versus-host disease. Blood. 2006;108:756-762.
Mannina D, Kröger N. Janus kinase inhibition for graft-versus-host disease: current status and future prospects. Drugs. 2019;79:1499-1509.
Link-Rachner CS, Sockel K, Schuetz C. Established and emerging treatments of skin GvHD. Front Immunol. 2022;13:838494.
Volc-Platzer B, Honigsmann H, Hinterberger W, Wolff K. Photochemotherapy improves chronic cutaneous graft-versus-host disease. J Am Acad Dermatol. 1990;23:220-228.
Greinix HT, Tanew A. UV treatment of chronic skin graft-versus-host disease-focus on UVA1 and extracorporeal photopheresis. Curr Probl Dermatol. 2012;43:116-131.
Janin A, Socie G, Devergie A, Aractingi S, Esperou H, Verola O, et al. Fasciitis in chronic graft-versus-host disease. A clinicopathologic study of 14 cases. Ann Intern Med. 1994;120:993-998.
Baum S, Pavlotsky F, Shpiro D, Trau H. PUVA treatment in sclerodermatoid spectrum of dermatologic diseases: our initial experience. Isr Med Assoc J. 2004;6:563-564.
Aragane Y, Kawada A, Maeda A, Isogai R, Isogai N, Tezuka T. Disseminated scleroderma of a Japanese patient successfully treated with bath PUVA photochemotherapy. J Cutan Med Surg. 2001;5:135-139.
Vogelsang GB, Wolff D, Altomonte V, Farmer E, Morison WL, Corio R, et al. Treatment of chronic graft-versus-host disease with ultraviolet irradiation and psoralen (PUVA). Bone Marrow Transplant. 1996;17:1061-1067.
Jampel RM, Farmer ER, Vogelsang GB. PUVA therapy for chronic cutaneous graft-vs-host disease. Arch Dermatol. 1991;127:1673-1678.
Stern RS, Lunder EJ. Risk of squamous cell carcinoma and methoxsalen (Psoralen) and UV-A radiation (PUVA). A meta-analysis. Arch Dermatol. 1998;134:1582-1585.
Calzavara Pinton P, Porta F, Izzi T, Venturini M, Capezzera R, Zane C, et al. Prospects for ultraviolet A1 phototherapy as a treatment for chronic cutaneous graft-versus-host disease. Haematologica. 2003;88:1169-1175.
Enk CD, Elad S, Vexler A, Kapelushnik J, Gorodetsky R, Kirschbaum M. Chronic graft-versus-host disease treated with UVB phototherapy. Bone Marrow Transplant. 1998;22:1179-1183.
Brazzelli V, Grasso V, Muzio F, Moggio E, Zecca M, Locatelli F, et al. Narrowband ultraviolet B phototherapy in the treatment of cutaneous graft-versus-host disease in oncohaematological paediatric patients. Br J Dermatol. 2010;162:404-409.
Fischer T, Alsins J. Treatment of psoriasis with trioxsalen baths and dysprosium lamps. Acta Derm Venereol. 1976;56:383-390.
Lowe NJ, Weingarten D, Bourget T, Moy LS. PUVA treatment for psoriasis: comparison of oral and bath-water delivery of 8-methoxypsoralen. J Am Acad Dermatol. 1986;14:754-760.
Collins P, Rogers S. Bath-water compared with oral delivery of 8-methoxypsoralen PUVA therapy for chronic plaque psoriasis. Br J Dermatol. 1992;127:392-395.
Cooper EJ, Herd RM, Priestly GC, Hunter A. A comparison of bathwater and oral delivery of 8-methoxypsoralen in PUVA therapy for plaque psoriasis. Clin Exp Dermatol. 2000;25:111-114.
Rogers MB. Standard oral versus bath-psoralens plus ultraviolet A. J Am Acad Dermatol. 1988;19:368.
Rodríguez-Granados MT, Carrascosa JM, Gárate T, Gómez-Díez S, Guimaraens-Juantorena D. Consensus document on bath-PUVA therapy. The Spanish Photobiology Group of the Spanish Academy of Dermatology and Venereology. Actas Dermosifiliogr. 2007;98:164-170.
Pavlotsky F, Hodak E, Ben Amitay D, Barzilai A. Role of bath psoralen plus ultraviolet A in early-stage mycosis fungoides. J Am Acad Dermatol. 2014;71:536-541.
Shaw BE. Graft versus host disease clinical trials: is it time for patients centered outcomes to be the primary objective? Curr Hematol Malig Rep. 2019;14:22-30.
Pavletic SZ, Martin P, Lee SJ, Mitchell S, Jacobsohn D, Cowen EW, et al. Measuring therapeutic response in chronic graft-versus-host disease: National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: IV. Response criteria working group report. Biol Blood Marrow Transplant. 2006;12:252-266.
Kassem R, Yarom N, Scope A, Babaev M, Trau H, Pavlotzky F. Treatment of erosive oral lichen planus with local ultraviolet B phototherapy. J Am Acad Dermatol. 2012;66:761-766.
Rostagno E, Campanati A, Mordini N, Cannici C, Cioce M, De Cecco V, et al. Phototherapy and topical treatments for cutaneous graft vs. host disease in haematopoietic stem cell transplantation patients: a scoping review. J Eur Acad Dermatol Venereol. 2022;36:1003-1015.
Leiter U, Kaskel P, Krähn G, Gottlöber P, Bunjes D, Peter RU, et al. Psoralen plus ultraviolet-A-bath photochemotherapy as an adjunct treatment modality in cutaneous chronic graft versus host disease. Photodermatol Photoimmunol Photomed. 2002;18:183-190.
Ghoreschi K, Thomas P, Penovici M, Ullmann J, Sander CA, Ledderose G, et al. PUVA-bath photochemotherapy and isotretinoin in sclerodermatous graft-versus-host disease. Eur J Dermatol. 2008;18:667-670.